101 related articles for article (PubMed ID: 15981228)
1. Fluid retention during arsenic trioxide treatment in acute promyelocytic leukemia.
Arai A; Kitano A; Kurosu T; Yamamoto K; Miki T; Murakami N; Miura O
Am J Hematol; 2005 Jul; 79(3):247-8. PubMed ID: 15981228
[No Abstract] [Full Text] [Related]
2. Arsenic trioxide induced acute flare-up of rheumatoid arthritis in a patient with APL.
Naithani R; Mahapatra M; Kumar R; Kumar A; Agrawal N
Ann Hematol; 2007 Feb; 86(2):151-2. PubMed ID: 17072614
[No Abstract] [Full Text] [Related]
3. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C
Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156
[No Abstract] [Full Text] [Related]
4. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment.
Au WY; Tam S; Kwong YL
Leuk Res; 2008 Feb; 32(2):357-8. PubMed ID: 17662385
[No Abstract] [Full Text] [Related]
5. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
[No Abstract] [Full Text] [Related]
6. Hyperleukocytosis from arsenic trioxide.
Levy M; Wofford MM; Powell BL; McLean TW
Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow necrosis in a patient with acute promyelocytic leukemia during re-induction therapy with arsenic trioxide.
Ishitsuka K; Shirahashi A; Iwao Y; Shishime M; Takamatsu Y; Takatsuka Y; Utsunomiya A; Suzumiya J; Hara S; Tamura K
Eur J Haematol; 2004 Apr; 72(4):280-4. PubMed ID: 15089767
[TBL] [Abstract][Full Text] [Related]
8. Impairment of heart rate variability control during arsenic trioxide treatment for acute promyelocytic leukemia.
Takeshita A; Uehara A; Shinjo K; Naito K; Sahara N; Yamazaki K; Katoh H; Kamikawa T; Ohnishi K; Maekawa M; Hayashi H; Ohno R
Leukemia; 2004 Mar; 18(3):647-8. PubMed ID: 14671633
[No Abstract] [Full Text] [Related]
9. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Lengfelder E; Schultheis B; Büchner T; Hehlmann R
Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
[No Abstract] [Full Text] [Related]
10. Arsenic-based therapy benefits leukemia patients.
FDA Consum; 2001; 35(1):4. PubMed ID: 11930925
[No Abstract] [Full Text] [Related]
11. Solid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemia.
Au WY; Kumana CR; Lam CW; Cheng VC; Shek TW; Chan EY; Liu R; Kwong YL
Leuk Res; 2007 Jan; 31(1):105-8. PubMed ID: 16725199
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide.
Wilkinson K
Clin J Oncol Nurs; 2001; 5(5):237-8. PubMed ID: 11899773
[No Abstract] [Full Text] [Related]
13. Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
Galm O; Fabry U; Osieka R
Leukemia; 2000 Feb; 14(2):343-4. PubMed ID: 10673758
[No Abstract] [Full Text] [Related]
14. Acute intestinal pseudo-obstruction after induction treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
Park JA; Yun JH; Kang HJ; Shin HY; Ahn HS
Pediatr Blood Cancer; 2008 Apr; 50(4):872-4. PubMed ID: 17635008
[TBL] [Abstract][Full Text] [Related]
15. Comparing two arsenic trioxide administration methods in APL therapy.
Zhou J; Meng R; Yang BF
Chin Med J (Engl); 2004 Sep; 117(9):1411-3. PubMed ID: 15377438
[No Abstract] [Full Text] [Related]
16. Oral arsenic treatment of leukemia and the risk of porphyria.
Au WY; Tam S; Fong BM; Kwong YL
Leuk Res; 2009 Apr; 33(4):598-600. PubMed ID: 18829106
[No Abstract] [Full Text] [Related]
17. Repeated arsenic trioxide intravenous infusion causes focal bone marrow necrosis in two acute promyelocytic leukemia patients.
Zhou J; Meng R; Sui XH; Yang BF
Chin Med Sci J; 2004 Dec; 19(4):281. PubMed ID: 15669187
[No Abstract] [Full Text] [Related]
18. Increased erythropoietin level and reticulocyte count during arsenic trioxide therapy.
Kajiguchi T; Yamamoto K; Sawa M; Emi N; Naoe T
Leukemia; 2005 Apr; 19(4):674-6. PubMed ID: 15690072
[No Abstract] [Full Text] [Related]
19. Evidence for basophilic differentiation of acute promyelocytic leukaemia cells during arsenic trioxide therapy.
Masamoto Y; Nannya Y; Arai S; Koike Y; Hangaishi A; Yatomi Y; Kurokawa M
Br J Haematol; 2009 Mar; 144(5):798-9. PubMed ID: 19036092
[No Abstract] [Full Text] [Related]
20. Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy.
Ninomiya M; Kajiguchi T; Yamamoto K; Kinoshita T; Emi N; Naoe T
Haematologica; 2006 Nov; 91(11):1571-2. PubMed ID: 17082016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
